CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Culture Supernatant
Mouse Monoclonal Antibody [Clone Ber-H2 + CD30/412 ]
|Application ||IHC, IF, FC|
|Other Accession||943, 1314|
|Isotype||Mouse / IgG's|
|Clone Names||Ber-H2 + CD30/412|
|Other Names||Tumor necrosis factor receptor superfamily member 8, CD30L receptor, Ki-1 antigen, Lymphocyte activation antigen CD30, CD30, TNFRSF8, CD30, D1S166E|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Culture Supernatant is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF- kappa-B.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Recognizes a single chain glycoprotein of 105/120kDa, identified as CD30/Ki-1. CD30 is synthesized as a 90kDa precursor, which is processed in the Golgi complex into a membrane-bound phosphorylated mature 105/120kDa glycoprotein. In Hodgkinā€™s disease, CD30/Ki-1 antigen is expressed by mononuclear-Hodgkin and multinucleated Reed-Sternberg cells. It is also expressed by the tumor cells of a majority of anaplastic large cell lymphomas as well as by a varying proportion of activated T and B cells. This MAb distinguishes large cell lymphomas derived from activated lymphoid cells from histiocytic malignancies and lymphomas derived from resting and precursor lymphoid cells or from anaplastic carcinomas. About one third of the Ki-1 positive lymphomas lack the leukocyte common antigen (CD45).
Schwarting R, Gerdes J, D�rkop H, Falini B, Pileri S, Stein H. Ber-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989;74:1678-89
If you have any additional inquiries please email technical services at firstname.lastname@example.org.